Compare Bristol-Myers Squibb Co (BMY) vs Lamb Weston Holdings Inc (LW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Lamb Weston Holdings Inc — how do they compare? Bristol-Myers Squibb Co trades at $58.59 (market cap $116.30B), while Lamb Weston Holdings Inc trades at $46.8 (market cap $6.42B). The key difference: Bristol-Myers Squibb Co is far larger — about 18.1× Lamb Weston Holdings Inc's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | LW | |
|---|---|---|
Market Cap | $116.30B | $6.42B |
Sector | Health | Consumer Staples |
52-Week High | $62.37 | $66.57 |
52-Week Low | $42.60 | $38.48 |
Enterprise Value | $152.24B | $10.38B |
Dividend Yield | 4.42% | 3.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Lamb Weston (LW) trades at $46.98, up 1.14% with a bullish technical signal and consistent earnings beats. The company shows strong operational cash flow of $868.3M in 2025 and maintains positive revenue growth, though net income margin declined to 4.61%. Recent news highlights the 'Focus to Win' strategy showing early traction with North America volume gains and cost savings.
Outlook remains cautiously optimistic with analyst consensus price target of $49.33 offering 5% upside. Key risks include ongoing securities litigation and margin pressure from competitive dynamics. Institutional sentiment leans positive with activist involvement signaling potential value creation opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →
